The value of innovation: the economics of targeted drugs for cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-03-21

AUTHORS

Cara C. Tigue, Karen A. Fitzner, Motasem Alkhatib, Eric Schmid, Charles L. Bennett

ABSTRACT

Oncology therapeutics have entered a new era, with the recent approval by the US Food and Drug Administration of 16 novel targeted agents. In many instances, these agents have led to breakthroughs in cancer care, such as imatinib for the treatment of chronic myeloid leukemia and bevacizumab for the treatment of colorectal, lung, and breast cancers. Toxicities of targeted agents are also novel-no longer primarily resulting in hematologic, gastrointestinal, and skin toxicities. As with all new and innovative therapies, the price tags for these agents are substantial, ranging from a mean per person annual cost of $13,000 to $100,000 in many cases. Despite the high cost of these drugs, the value of these agents has been important. In this paper, we review the concepts of value and cost effectiveness as they apply to targeted cancer agents and provide some initial insights on the economics of targeted oncology drugs. More... »

PAGES

113-119

References to SciGraph publications

  • 2005-06-03. The realisation of targeted antitumour therapy in BRITISH JOURNAL OF CANCER
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s11523-007-0043-8

    DOI

    http://dx.doi.org/10.1007/s11523-007-0043-8

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1039883351


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "VA Center for Management of Complex Chronic Care, Jesse Brown VA Medical Center, Chicago, IL, USA", 
              "id": "http://www.grid.ac/institutes/grid.280892.9", 
              "name": [
                "The Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA", 
                "The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA", 
                "VA Center for Management of Complex Chronic Care, Jesse Brown VA Medical Center, Chicago, IL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tigue", 
            "givenName": "Cara C.", 
            "id": "sg:person.013156761617.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013156761617.16"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA", 
              "id": "http://www.grid.ac/institutes/grid.16753.36", 
              "name": [
                "The Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA", 
                "The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fitzner", 
            "givenName": "Karen A.", 
            "id": "sg:person.01220574267.85", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220574267.85"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA", 
              "id": "http://www.grid.ac/institutes/grid.16753.36", 
              "name": [
                "The Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA", 
                "The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Alkhatib", 
            "givenName": "Motasem", 
            "id": "sg:person.01165673113.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165673113.28"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA", 
              "id": "http://www.grid.ac/institutes/grid.16753.36", 
              "name": [
                "The Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA", 
                "The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schmid", 
            "givenName": "Eric", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Northwestern University, 303 E. Chicago Avenue, Olson Pavilion, Suite 8250, 60611, Chicago, IL, USA", 
              "id": "http://www.grid.ac/institutes/grid.16753.36", 
              "name": [
                "The Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA", 
                "The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA", 
                "VA Center for Management of Complex Chronic Care, Jesse Brown VA Medical Center, Chicago, IL, USA", 
                "Northwestern University, 303 E. Chicago Avenue, Olson Pavilion, Suite 8250, 60611, Chicago, IL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bennett", 
            "givenName": "Charles L.", 
            "id": "sg:person.01100705232.37", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100705232.37"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.bjc.6602602", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009656513", 
              "https://doi.org/10.1038/sj.bjc.6602602"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2007-03-21", 
        "datePublishedReg": "2007-03-21", 
        "description": "Oncology therapeutics have entered a new era, with the recent approval by the US Food and Drug Administration of 16 novel targeted agents. In many instances, these agents have led to breakthroughs in cancer care, such as imatinib for the treatment of chronic myeloid leukemia and bevacizumab for the treatment of colorectal, lung, and breast cancers. Toxicities of targeted agents are also novel-no longer primarily resulting in hematologic, gastrointestinal, and skin toxicities. As with all new and innovative therapies, the price tags for these agents are substantial, ranging from a mean per person annual cost of $13,000 to $100,000 in many cases. Despite the high cost of these drugs, the value of these agents has been important. In this paper, we review the concepts of value and cost effectiveness as they apply to targeted cancer agents and provide some initial insights on the economics of targeted oncology drugs.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s11523-007-0043-8", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1036678", 
            "issn": [
              "1776-2596", 
              "1776-260X"
            ], 
            "name": "Targeted Oncology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "2"
          }
        ], 
        "keywords": [
          "person annual costs", 
          "treatment of colorectal", 
          "chronic myeloid leukemia", 
          "skin toxicity", 
          "cancer care", 
          "breast cancer", 
          "myeloid leukemia", 
          "US Food", 
          "Drug Administration", 
          "innovative therapies", 
          "oncology therapeutics", 
          "recent approval", 
          "cancer agents", 
          "oncology drugs", 
          "drugs", 
          "cancer", 
          "treatment", 
          "cost effectiveness", 
          "annual cost", 
          "agents", 
          "toxicity", 
          "bevacizumab", 
          "colorectal", 
          "imatinib", 
          "lung", 
          "therapy", 
          "leukemia", 
          "administration", 
          "care", 
          "therapeutics", 
          "approval", 
          "new era", 
          "high cost", 
          "food", 
          "cases", 
          "initial insights", 
          "values", 
          "effectiveness", 
          "era", 
          "means", 
          "cost", 
          "breakthrough", 
          "insights", 
          "price tag", 
          "value of innovation", 
          "instances", 
          "tags", 
          "concept", 
          "innovation", 
          "economics", 
          "concept of value", 
          "paper"
        ], 
        "name": "The value of innovation: the economics of targeted drugs for cancer", 
        "pagination": "113-119", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1039883351"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s11523-007-0043-8"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s11523-007-0043-8", 
          "https://app.dimensions.ai/details/publication/pub.1039883351"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:17", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_448.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s11523-007-0043-8"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-007-0043-8'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-007-0043-8'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-007-0043-8'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-007-0043-8'


     

    This table displays all metadata directly associated to this object as RDF triples.

    150 TRIPLES      22 PREDICATES      78 URIs      69 LITERALS      6 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s11523-007-0043-8 schema:about anzsrc-for:11
    2 anzsrc-for:1112
    3 schema:author N4bd25c29fd5141cf9fdfe0268bbec8fc
    4 schema:citation sg:pub.10.1038/sj.bjc.6602602
    5 schema:datePublished 2007-03-21
    6 schema:datePublishedReg 2007-03-21
    7 schema:description Oncology therapeutics have entered a new era, with the recent approval by the US Food and Drug Administration of 16 novel targeted agents. In many instances, these agents have led to breakthroughs in cancer care, such as imatinib for the treatment of chronic myeloid leukemia and bevacizumab for the treatment of colorectal, lung, and breast cancers. Toxicities of targeted agents are also novel-no longer primarily resulting in hematologic, gastrointestinal, and skin toxicities. As with all new and innovative therapies, the price tags for these agents are substantial, ranging from a mean per person annual cost of $13,000 to $100,000 in many cases. Despite the high cost of these drugs, the value of these agents has been important. In this paper, we review the concepts of value and cost effectiveness as they apply to targeted cancer agents and provide some initial insights on the economics of targeted oncology drugs.
    8 schema:genre article
    9 schema:inLanguage en
    10 schema:isAccessibleForFree false
    11 schema:isPartOf N37862605d7d541e0829d3e77a25319ba
    12 N51b48e2030664207b62da9143d4a2827
    13 sg:journal.1036678
    14 schema:keywords Drug Administration
    15 US Food
    16 administration
    17 agents
    18 annual cost
    19 approval
    20 bevacizumab
    21 breakthrough
    22 breast cancer
    23 cancer
    24 cancer agents
    25 cancer care
    26 care
    27 cases
    28 chronic myeloid leukemia
    29 colorectal
    30 concept
    31 concept of value
    32 cost
    33 cost effectiveness
    34 drugs
    35 economics
    36 effectiveness
    37 era
    38 food
    39 high cost
    40 imatinib
    41 initial insights
    42 innovation
    43 innovative therapies
    44 insights
    45 instances
    46 leukemia
    47 lung
    48 means
    49 myeloid leukemia
    50 new era
    51 oncology drugs
    52 oncology therapeutics
    53 paper
    54 person annual costs
    55 price tag
    56 recent approval
    57 skin toxicity
    58 tags
    59 therapeutics
    60 therapy
    61 toxicity
    62 treatment
    63 treatment of colorectal
    64 value of innovation
    65 values
    66 schema:name The value of innovation: the economics of targeted drugs for cancer
    67 schema:pagination 113-119
    68 schema:productId N54beae2287a243e39a79af876a3c9c5f
    69 Na873976df35947a7b35993bc3056122c
    70 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039883351
    71 https://doi.org/10.1007/s11523-007-0043-8
    72 schema:sdDatePublished 2022-01-01T18:17
    73 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    74 schema:sdPublisher Ndae2530938e34cd5accffa4c108cb98b
    75 schema:url https://doi.org/10.1007/s11523-007-0043-8
    76 sgo:license sg:explorer/license/
    77 sgo:sdDataset articles
    78 rdf:type schema:ScholarlyArticle
    79 N37862605d7d541e0829d3e77a25319ba schema:volumeNumber 2
    80 rdf:type schema:PublicationVolume
    81 N438ba9f04f92467196a2a3e3a1b48eb3 rdf:first sg:person.01165673113.28
    82 rdf:rest Nac1dcfd25eb9465b872f3ab580e7952c
    83 N4bd25c29fd5141cf9fdfe0268bbec8fc rdf:first sg:person.013156761617.16
    84 rdf:rest Nbaf92e2937814030aa580a0cd81b55e8
    85 N51b48e2030664207b62da9143d4a2827 schema:issueNumber 2
    86 rdf:type schema:PublicationIssue
    87 N53f46b69e86440fca231a35f30732783 schema:affiliation grid-institutes:grid.16753.36
    88 schema:familyName Schmid
    89 schema:givenName Eric
    90 rdf:type schema:Person
    91 N54beae2287a243e39a79af876a3c9c5f schema:name dimensions_id
    92 schema:value pub.1039883351
    93 rdf:type schema:PropertyValue
    94 Na873976df35947a7b35993bc3056122c schema:name doi
    95 schema:value 10.1007/s11523-007-0043-8
    96 rdf:type schema:PropertyValue
    97 Nac1dcfd25eb9465b872f3ab580e7952c rdf:first N53f46b69e86440fca231a35f30732783
    98 rdf:rest Nf5f052b7e51a4b8682f1a5cbfa429452
    99 Nbaf92e2937814030aa580a0cd81b55e8 rdf:first sg:person.01220574267.85
    100 rdf:rest N438ba9f04f92467196a2a3e3a1b48eb3
    101 Ndae2530938e34cd5accffa4c108cb98b schema:name Springer Nature - SN SciGraph project
    102 rdf:type schema:Organization
    103 Nf5f052b7e51a4b8682f1a5cbfa429452 rdf:first sg:person.01100705232.37
    104 rdf:rest rdf:nil
    105 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    106 schema:name Medical and Health Sciences
    107 rdf:type schema:DefinedTerm
    108 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    109 schema:name Oncology and Carcinogenesis
    110 rdf:type schema:DefinedTerm
    111 sg:journal.1036678 schema:issn 1776-2596
    112 1776-260X
    113 schema:name Targeted Oncology
    114 schema:publisher Springer Nature
    115 rdf:type schema:Periodical
    116 sg:person.01100705232.37 schema:affiliation grid-institutes:grid.16753.36
    117 schema:familyName Bennett
    118 schema:givenName Charles L.
    119 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100705232.37
    120 rdf:type schema:Person
    121 sg:person.01165673113.28 schema:affiliation grid-institutes:grid.16753.36
    122 schema:familyName Alkhatib
    123 schema:givenName Motasem
    124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165673113.28
    125 rdf:type schema:Person
    126 sg:person.01220574267.85 schema:affiliation grid-institutes:grid.16753.36
    127 schema:familyName Fitzner
    128 schema:givenName Karen A.
    129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220574267.85
    130 rdf:type schema:Person
    131 sg:person.013156761617.16 schema:affiliation grid-institutes:grid.280892.9
    132 schema:familyName Tigue
    133 schema:givenName Cara C.
    134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013156761617.16
    135 rdf:type schema:Person
    136 sg:pub.10.1038/sj.bjc.6602602 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009656513
    137 https://doi.org/10.1038/sj.bjc.6602602
    138 rdf:type schema:CreativeWork
    139 grid-institutes:grid.16753.36 schema:alternateName Northwestern University, 303 E. Chicago Avenue, Olson Pavilion, Suite 8250, 60611, Chicago, IL, USA
    140 The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    141 schema:name Northwestern University, 303 E. Chicago Avenue, Olson Pavilion, Suite 8250, 60611, Chicago, IL, USA
    142 The Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    143 The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    144 VA Center for Management of Complex Chronic Care, Jesse Brown VA Medical Center, Chicago, IL, USA
    145 rdf:type schema:Organization
    146 grid-institutes:grid.280892.9 schema:alternateName VA Center for Management of Complex Chronic Care, Jesse Brown VA Medical Center, Chicago, IL, USA
    147 schema:name The Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    148 The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    149 VA Center for Management of Complex Chronic Care, Jesse Brown VA Medical Center, Chicago, IL, USA
    150 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...